Publications

Peripheral T- and natural killer-cell lymphomas: ESMO-EHA Clinical Practice Guideline for diagnosis, treatment, and follow-up.

d’Amore, F., Federico, M., de Leval, L., Ellin, F., Hermine, O., Kim, W.S., Lemonnier, F., Vermaat, J.S.P., Wulf, G., Buske, C., Dreyling, M., Jerkeman, M. and the ESMO and EHA Guidelines Committees (2025)

HemaSphere, 9: e70128.

 

EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma.

Jerkeman, M., Aurer, I., Campo, E., Cheah, C.Y., Clark, J., Doorduijn, J., Eyre, T.A., Fehr, M., Giné, E., Gomes da Silva, M., Klener, P., Ladetto, M., Ribrag, V., Shpilberg, O., Walewski, J., Dreyling, M. and the EHA Guidelines Committee and the European MCL Network (2025)

HemaSphere, 9: e70233.

 

Large B-cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up.

Thieblemont, C., Gomes Da Silva, M., Leppä, S., Lenz, G., Cottereau, A.-S., Fox, C., Lopez-Guillermo, A., Illidge, T., Jurczak, W., Eich, H., Aurer, I., Trneny, M., Rosenwald, A., Davies, A., Zwezerijnen, B., Bolanos, N., Marković, M., Jais, J.-P., Broussais, F., Dreyling, M., Vitolo, U., Tilly, H. and Kersten, M.J. (2025)

HemaSphere, 9: e70207.

Bridging gaps in clinical trial accessibility and reimbursement for large B‐cell lymphoma therapies across Europe.

Broussais F, Pennings E, Bolanos N, Warwick L, Doeswijk R, Quinonez G, Lebeda A, Gomes Da Silva M, Leppä S, Lenz G, Cottereau AS, Fox C, Lopez‐Guillermo A, Illidge T, Jurczak W, Eich H, Aurer I, Trneny M, Rosenwald AA, Davies A, Zwezerijnen B, Jais JP, Dreyling M, Vitolo U, Tilly H, Thieblemont C, Kersten MJ.

Hemasphere 2025; 9:e70204.

Analysis of safety and efficacy of CARMEN, GMALL, LMB, and other intensive chemotherapy combinations in an international series of HIV-positive patients with Burkitt lymphoma: a study of the HIV Lymphoma Network of the European Hematology Association.

Ferreri AJM, Erbella F, Schommers P, Ribera JM, Vasseur L, Varga L, Hoffman C, Navaroo JT, Besson C, Aurer I, Ravano E, Angelillo P, Bellman R, Cavallo F, Spina M, Hubel K, Hentrich M, Re A.

ASH 2025, abstr 0478

Human immunodeficiency virus-associated lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Hübel K, Bower M, Aurer I, Bastos-Oreiro M, Besson C, Brunnberg U, Cattaneo C, Collins S, Cwynarski K, Dalla Pria A, Hentrich M, Hoffmann C, Kersten MJ, Montoto S, Navarro JT, Oksenhendler E, Re A, Ribera JM, Schommers P, von Tresckow B, Buske C, Dreyling M, Davies A.

Ann Oncol 2024; doi.org/10.1016/j.annonc.2024.06.003.

Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Ferreri AJM et al.

Ann Oncol 2024; 35:491 – 507.

Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network

Dreyling M, Doorduijn J, Giné E, Jerkeman M, Walewski J, Hutchings M et al.

Lancet 2024; 403: 2293–306.

High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network

Hermine O, Jiang L, Walewski J, Bosly A, Thieblemont C, Szymczyk M, Pott C, Salles G, Feugier P, Hübel K, Haioun C, Casasnovas RO, Schmidt C, Bouabdallah K, Ribrag V, Kanz L, Dürig J, Metzner B, Sibon D, Cheminant M, Burroni B, Klapper W, Hiddemann W, Unterhalt M, Hoster E, Dreyling M; European Mantle Cell Lymphoma Network.

J Clin Oncol 2023; 41: 479-84.

La Cantera: “A Star Is Born” in Hematology

Dreyling M, Manni M, Federico M.

Hemasphere 2023; 7:e866.

Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)

Scheubeck G, Jiang L, Hermine O, Kluin-Nelemans HC, Schmidt C, Unterhalt M, Rosenwald A, Klapper W, Evangelista A, Ladetto M, Jerkeman M, Ferrero S, Dreyling M*, Hoster E*.

Leukemia. 2023; 37:1887-94.

Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study

Hess G, Dreyling M, Oberic L, Gine E, Zinzani PL, Linton K, Vilmar A, Jerkeman M, Chen JMH, Ohler A, Stilgenbauer S, Thieblemont C, Lambert J, Zilioli VR, Sancho JM, Ubieto AJ, Fischer L, Eyre TA, Keeping S, Park JE, Wu JJ, Siddiqi R, Reitan J, Wade S, Salles G.

Br J Haematol 2023; 202:749-59.

A Lack of Diversity, Equity, and Inclusion in Clinical Research Has Direct Impact on Patient Care

El-Galaly TC, Gaidzik VI, Gaman MA, Antic D, Okosun J, Copland M, Sexl V, Fielding AK, Doeswijk R, Parker H, Dreyling M, Döhner K, Almeida AM, Macintyre E, Gribben JG, Grønbæk K.

Hemasphere 2023; 7:e842.

Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)

Novak U, Fehr M, Schär S, Dreyling M, Schmidt C, Derenzini E, Zander T, Hess G, Mey U, Ferrero S, Mach N, Boccomini C, Böttcher S, Voegeli M, Cairoli A, Ivanova VS, Menter T, Dirnhofer S, Scheibe B, Gadient S, Eckhardt K, Zucca E, Driessen C, Renner C.

EClinicalMedicine. 2023; 64:102221.

Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma

Hess G, Dreyling M, Oberic L, Gine E, Zinzani PL, Linton K, Vilmar A, Jerkeman M, Chen JMH, Ohler A, Stilgenbauer S, Thieblemont C, Lambert J, Zilioli VR, Sancho JM, Jimenez-Ubieto A, Fischer L, Eyre TA, Keeping S, Park JE, Wu JJ, Nunes A, Reitan J, Wade SW, Salles G.

Leuk Lymphoma 2023; 16:1-12.